These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. Kornblau SM; Qutub A; Yao H; York H; Qiu YH; Graber D; Ravandi F; Cortes J; Andreeff M; Zhang N; Coombes KR PLoS One; 2013; 8(10):e78453. PubMed ID: 24223100 [TBL] [Abstract][Full Text] [Related]
25. Hoxa9 and Flt3 signaling synergistically regulate an early checkpoint in lymphopoiesis. Gwin KA; Shapiro MB; Dolence JJ; Huang ZL; Medina KL J Immunol; 2013 Jul; 191(2):745-54. PubMed ID: 23772038 [TBL] [Abstract][Full Text] [Related]
26. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460 [TBL] [Abstract][Full Text] [Related]
27. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871 [TBL] [Abstract][Full Text] [Related]
28. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595 [TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512 [TBL] [Abstract][Full Text] [Related]
30. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. Annaloro C; Onida F; Saporiti G; Lambertenghi Deliliers G Curr Pharm Biotechnol; 2011 Feb; 12(2):217-25. PubMed ID: 21044004 [TBL] [Abstract][Full Text] [Related]
31. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408 [TBL] [Abstract][Full Text] [Related]
32. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518 [TBL] [Abstract][Full Text] [Related]
33. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Bonnet D; Dick JE Nat Med; 1997 Jul; 3(7):730-7. PubMed ID: 9212098 [TBL] [Abstract][Full Text] [Related]
34. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Levis M; Murphy KM; Pham R; Kim KT; Stine A; Li L; McNiece I; Smith BD; Small D Blood; 2005 Jul; 106(2):673-80. PubMed ID: 15797998 [TBL] [Abstract][Full Text] [Related]
35. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470 [TBL] [Abstract][Full Text] [Related]
36. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589 [TBL] [Abstract][Full Text] [Related]
37. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34 Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777 [TBL] [Abstract][Full Text] [Related]
38. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Ho TC; LaMere M; Stevens BM; Ashton JM; Myers JR; O'Dwyer KM; Liesveld JL; Mendler JH; Guzman M; Morrissette JD; Zhao J; Wang ES; Wetzler M; Jordan CT; Becker MW Blood; 2016 Sep; 128(13):1671-8. PubMed ID: 27421961 [TBL] [Abstract][Full Text] [Related]
40. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Hope KJ; Jin L; Dick JE Nat Immunol; 2004 Jul; 5(7):738-43. PubMed ID: 15170211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]